Mamani-Cancino AD, Veloz-Martínez MG, Casasola-Busteros I, Moctezuma-Meza C, García-Cebada JM

Language: Spanish
References: 15
Page: 369-376
PDF size: 525.50 Kb.

ABSTRACT

Background: Her-2/neu is an oncogen related with a poor prognosis and high agresivity when overexpressed in breast cáncer.
Main objective was analyze the frecuency of positivity or negativity ofller/neu in patients with breast cáncer after surgery and their relationship with hormone receptors.
We perfomed a longitudinal, retrospective, descriptive and observational trial in all patients included in the Patology Service with a detcrmination of Her-2/neu and hormone receptors analysis, between January Ist 2007 and December 31 st 2009.We used descriptive stadistic and association tests with correlation coefficients.
We analyze 893 patients. The age range was between 24 and 94 years. The 16.% of all cases overexpressed Her-2/neu (150 patients). The 4.8% (43 patients) were included in the FISII test resulting in 29 positives to Her-2/neu. There were a total of 179 cases overexpressed. Negative estrogen receptores cases were 23%, negative progesterone receptores cases were 28% and triple negative receptors cases were 19%.
We analyzed independient variables with Student I resulting age with P = 0.294. We analyzed distribution variables with Pearson test resulting in negative estrogen receptors with a P = 0.0001 negative progesterone receptres with a P= 0.0001 and triple negative receptors P= 0.0001.
Relationship between hormone receptors and Her-2/neu in proporlionaly inverse in other vvords when a high hormone receptors negativitvis present there is algo a Her-2/neu highly overexpressed.

REFERENCES

1. Akivama T. Sudo C. Ogawara H. Toyoshima K. Yamamoto T. The product of the human c-erB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986;232(4758):1644-1650.

2. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Lilis L, et al. Expression of ras p21, p53 and c-erbB-2in advanced breast cancer and response to first line hormonal therapy. Brt Cancer 1995;72:1259-1266.

3. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of Her-2/neu gene amplification human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.

4. Borg A, Baldetorp B, Femo M, Killander D, Olsson II, Ryden S, Sigurdsson H. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137-144.

5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987;235(4785):177-182.

6. Slamon IXI, Godolphin W, Jones LA, Ilolt JA, Wong SG, Keith WJ, Levin WJ, Stuart SG, Udove J, Ulldrich A, et al. Studies of the Her-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-12.

7. Egervari K, Szoliosi N, Nemos Z. Immunohistochemical antibodies in brest cancer Her-2/neu diagnostics. A comparative immunohistochemical and fluorescence in situ hybridization study. Tumour Biol 2008;29:18-27.

8. Jones A. Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why? Royal Free Hospital Clinical Oncology. London. UK, 2003 European Society for Medical Oncology.

9. Persons DI, Bui MM, Lowery MC, Mark III, Yung JF, et al. Fluorescence in situ hybridization for detection of Her-2/ neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci 2000;30:41-48.

10. Berns EM, Foekens JA, Staveren IL, Van Putten WL, De Koning HY, Portengen II, Klijn JG. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995;159:1-18.

11. Berry DA, Muss HB, Thor AD, et al. Her-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive. Node positive breast cancer. Clin Oncol 2000; 18:3471-3479.

12. De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, Ruggiero A, Marinelli A, et al. Twentyyear results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen eflicaccy in early breast cancer. Clin Cancer Res 2003;9: 1039-46.

13. Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, et al. Comparison of Her-2/neu status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. Clin Oncol 2005;23:4287-4297.

14. Borg A, Tandon AK, Sigurdsson H, Clark GM, Femo M, Fuqua SAW, et al. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-4337.

15. Carlomagno C, Perrone F, Gallo C, De Laurentis M, Lauria R, et al. Her-2/neu overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. Clin Oncol 1996;10:2702-2708.